BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AP203 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AP203\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05473156-2349@assetmemo.bio
DTSTAMP:20261121T005356Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AP203: Phase 1/2 readout est. (NCT05473156)
DESCRIPTION:AP203\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Study
  to Investigate the Safety\, Pharmacokinetics\, and Clinical Activity of A
 P203 in Patients with Locally Advanced or Metastatic Solid Tumors\, and Ex
 pansion to Selected Malignancies\nEstimated primary completion: December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ap203#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05473156
URL:https://assetmemo.bio/drug/ap203#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
